Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Candel Therapeutics, Inc.NASDAQ: CADL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.44M rose 56.6% year over year, ahead of the +39.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 36.4% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $3.72B (+20811.6%) for the fiscal year ending Dec 2026, a step up from the +26.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.44M+36.4% QoQ
- Last fiscal yearDec 2025
- $17.77M+26.4% YoY
- LTMMar 2026
- $20.1M+39.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 17.77M USD
- Year-over-year change
- +26.4%
- 4-year CAGR
- +13.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.77M | +26.4% |
| FY2024 | 2024-12-31 | 14.06M | +1.2% |
| FY2023 | 2023-12-31 | 13.89M | -1.2% |
| FY2022 | 2022-12-31 | 14.06M | +31.7% |
| FY2021 | 2021-12-31 | 10.67M | — |
Selling, General & Admin vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.9% is the 2nd highest of 10, against a peer median of +12.6%.
- Over three fiscal years its annual growth of +8.1% compares with a peer median of +9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $176.24M USD | +26.9% | +75.5% | 81.2% | |
| LTM Sep 2026 | $153.2M USD | -3.3% | +13.5% | 40.4% | |
| LTM Mar 2026 | $72.24M USD | -5.3% | -7.5% | 31.8% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $33.29M USD | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $22.18M USD | -32.4% | -9.0% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥21.46M CNY | +128.2% | -71.8% | — |
| LTM Mar 2026 | $20.1M USD | +39.9% | +8.1% | — | |
| LTM Mar 2026 | $15.81M USD | +34.6% | +50.4% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $13.37M USD | +14.2% | +38.8% | 167162.5% |
| Peer median (excluding CADL) | — | +12.6% | +9.8% | 40.4% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125K | 125K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 125K | 125K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 15.18M | 20.79M | 24.51M | 19.31M | 30.5M |
| Selling, General & Admin | 10.67M | 14.06M | 13.89M | 14.06M | 17.77M |
| Operating Expenses | 24.78M | 34.8M | 38.39M | 33.37M | 48.27M |
| Depreciation & Amortization | 232K | 778K | 960K | 990K | 845K |
| EBITDA | (24.42M) | (16.31M) | (34.38M) | (52.1M) | (35.22M) |
| EBITDA Margin | -19534.4% | -13046.4% | — | — | — |
| Operating Income | (24.65M) | (34.67M) | (38.39M) | (33.37M) | (48.27M) |
| Operating Margin | -19720.0% | -27739.2% | — | — | — |
| Interest Income | 0 | 1.22M | 2.08M | 1.09M | 3.92M |
| Interest Expense | 53K | 1.71M | 2.6M | 2.09M | 2.12M |
| Other Income / Expenses | (10.4M) | 15.93M | 452K | (21.81M) | 10.08M |
| Income Before Tax | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Pre-Tax Margin | -28899.2% | -15035.2% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Net Margin | -28899.2% | -15035.2% | — | — | — |
| EPS (Basic) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| EPS (Diluted) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| Weighted Avg Shares | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
| Weighted Avg Shares (Diluted) | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.